CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2016—ArcherDX announced three targeted next-generation sequencing assays to capture and identify known and novel gene fusions, point mutations, and relative expression levels in myeloid and lymphoid origin malignancies. The Archer FusionPlex Blood Cancer panels use Archer’s proprietary Anchored Multiplex PCR to detect known and novel fusions from RNA. AMP also tags each input fragment with a barcode for molecular quantification for expression level detection and added confidence in mutation detection. Archer FusionPlex Heme v2, Myeloid, and ALL panels each interrogate 80 to 90 genes, simultaneously detecting fusions, critical point mutations, and expression levels when analyzed using the Archer Analysis bioinformatics platform.
ArcherDX, 303-357-9001